Tags

Type your tag names separated by a space and hit enter

Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Bone Marrow Transplant. 2005 Jan; 35(2):159-64.BM

Abstract

Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM patients were transplanted in our centre between 1995 and 2002. Following ASCT, 35% of patients were in complete remission (CR) and 60% were in partial remission (PR). The median progression-free (PFS) and overall (OS) survival from transplantation were 29.5 and 68.8 months, respectively. Transplant-related mortality (TRM) was 3%. On multivariate analysis, factors associated with significantly shorter OS were lack of CR after transplant (P = 0.002, hazard ratio (HR): 3.1), stage 3 according to ISS (P = 0.001, HR: 3.0) and age at transplant over 60 years (P = 0.035, HR: 2.0). The status of disease before ASCT did not significantly affect PFS and OS after transplantation. We conclude that ASCT is a safe and effective procedure in MM patients, associated with low TRM. The survival after ASCT was dependent on response after ASCT, stage according to ISS and age.

Authors+Show Affiliations

Department of Internal Medicine - Haematooncology, Masaryk University Hospital, Jihlavska 20, Brno 625 00, Czech Republic. mkrejci@fnbrno.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15543200

Citation

Krejci, M, et al. "Prognostic Factors for Survival After Autologous Transplantation: a Single Centre Experience in 133 Multiple Myeloma Patients." Bone Marrow Transplantation, vol. 35, no. 2, 2005, pp. 159-64.
Krejci M, Buchler T, Hajek R, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant. 2005;35(2):159-64.
Krejci, M., Buchler, T., Hajek, R., Svobodnik, A., Krivanova, A., Pour, L., Adam, Z., Mayer, J., & Vorlicek, J. (2005). Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplantation, 35(2), 159-64.
Krejci M, et al. Prognostic Factors for Survival After Autologous Transplantation: a Single Centre Experience in 133 Multiple Myeloma Patients. Bone Marrow Transplant. 2005;35(2):159-64. PubMed PMID: 15543200.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. AU - Krejci,M, AU - Buchler,T, AU - Hajek,R, AU - Svobodnik,A, AU - Krivanova,A, AU - Pour,L, AU - Adam,Z, AU - Mayer,J, AU - Vorlicek,J, PY - 2004/11/16/pubmed PY - 2005/5/18/medline PY - 2004/11/16/entrez SP - 159 EP - 64 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 35 IS - 2 N2 - Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM patients were transplanted in our centre between 1995 and 2002. Following ASCT, 35% of patients were in complete remission (CR) and 60% were in partial remission (PR). The median progression-free (PFS) and overall (OS) survival from transplantation were 29.5 and 68.8 months, respectively. Transplant-related mortality (TRM) was 3%. On multivariate analysis, factors associated with significantly shorter OS were lack of CR after transplant (P = 0.002, hazard ratio (HR): 3.1), stage 3 according to ISS (P = 0.001, HR: 3.0) and age at transplant over 60 years (P = 0.035, HR: 2.0). The status of disease before ASCT did not significantly affect PFS and OS after transplantation. We conclude that ASCT is a safe and effective procedure in MM patients, associated with low TRM. The survival after ASCT was dependent on response after ASCT, stage according to ISS and age. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/15543200/Prognostic_factors_for_survival_after_autologous_transplantation:_a_single_centre_experience_in_133_multiple_myeloma_patients_ L2 - https://doi.org/10.1038/sj.bmt.1704728 DB - PRIME DP - Unbound Medicine ER -